OncoMatch/Clinical Trials/NCT05821166
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Is NCT05821166 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies moderate Whole Body Hyperthermia (mWBH) for oncology.
Treatment: moderate Whole Body Hyperthermia (mWBH) — Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: BRAF wild-type
missing BRAF-V600 mutation
Required: HPV associated
HPV-associated squamous cell carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Grade: high-grade
treatment-naive stage IV with multiple metastases; metastatic or inoperable pancreatic cancer; metastatic high-grade sarcoma; metastatic or loco-regionally recurrent HPV-associated squamous cell carcinoma; metastatic, castration-resistant prostate cancer
Performance status
WHO 0–2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify